Synairgen Share Discussion Threads

[pdt] 13/4/2020 09:27

New paper on the value of pretreatment with IFN in respect of this type of coronavirus.

SARS-CoV-2 sensitive to type I interferon pretreatment.



"Our results indicate that while SARS-CoV-2 maintains similar viral replication kinetics to SARS-CoV in Vero cell, the novel CoV is much more sensitive to IFN-I pretreatment".

Comment: So you can imagine lots of scenarios where you might want to treat vulnerable people in a prophylactic way with SNG001 (if trial successful) whenever there is a local outbreak eg care homes

[peachie 74] 13/4/2020 09:11

Thanks Nobby.

I presume though this could be viewed as a good thing for SNG by association ?

[nobbygnome] 13/4/2020 08:54

>> peachie

But it's definitely not SNG001 being used in the Solidarity trial. The link below says the drug is given as 'daily injection for 6 days'. I repeat this is rebif not SNG001.

[peachie 74] 13/4/2020 08:51

Above quote from

[peachie 74] 13/4/2020 08:50

Drug repurposing Edit

Drug repositioning (also known as drug repurposing, re-profiling, re-tasking or therapeutic switching) is the repurposing of an approved drug for the treatment of another disease or medical condition.[4]

Studies Edit

Chloroquine Edit
Chloroquine is an anti-malarial medication that is also used against some auto-immune diseases. On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.[5] New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.[6]

On March 28, 2020 the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).[7] The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.[8][9] The CDC has stated that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.[10] Doctors have said they are using the drug when "there's no other option".[11] On April 9th, the National Institutes of Health began the first clinical trial to assess whether hydroxychloroquine is safe and effective to treat COVID-19.[11][12]

There are several studies underway on prophylactic use of chloroquine, especially in healthcare workers and their families. A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.[13] Large studies are underway at Duke University and the University of Oxford. NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.[14]

Favipiravir Edit
Chinese clinical trials in Wuhan and Shenzhen claimed to show that favipiravir was "clearly effective".[15] Of 35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.[16] In a study conducted in Wuhan on 240 patients with pneumonia half were given favipiravir and half received umifenovir. The researchers found that patients recovered from coughs and fevers faster when treated with favipiravir, but that there was no change in how many patients in each group progressed to more advanced stages of illness that required treatment with a ventilator.[17]

On 22 March 2020, Italy approved the drug for experimental use against COVID-19 and began conducting trials in the three regions most affected by the disease.[18] The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.[19] On 2 April 2020, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.[20] According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.[21]

The drug may be less effective in severe cases of illness where the virus has already multiplied. It may not be safe for use by pregnant women or those trying to conceive. [16]

Interferon beta Edit
UK biotech firm Synairgen started conducting trials on IFN-β, a drug that was originally developed to treat COPD.[5] IFN-β will be included in the international Solidarity Trial in combination with the HIV drugs Lopinavir and Ritonavir.[22]

Lopinavir/ritonavir Edit
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".[23][24] The drugs were designed to inhibit HIV from replicating by binding to the protease. A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.[25]

There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS, since it is unlikely that a drug developed specifically against HIV will work for a very different virus (it is more likely that general-purpose antivirals will work).[1] The WHO included lopinavir/ritonavir in the international Solidarity trial.[5]

Remdesivir Edit
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission. Some early pretrial studies suggest that Remdesivir may have a high genetic barrier to resistance.[26] Data from clinical trials is expected in April 2020.[27]

There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.[25] The Feinstein Institute of the Northwell Health system has partnered with Gilead Sciences on phase III clinical trials for remdesivir.[28]

[nobbygnome] 13/4/2020 08:47

It's not SNG001 as it's injected so probably rebif! Injected interferon beta has little chance of working IMHO....

[nobbygnome] 13/4/2020 08:41

So it is a different trial. However, from the information I can see it is impossible to tell if it is inhaled interferon beta or sub cutaneous. Where it talks about interferon beta it says 'used to treat multiple sclerosis'. Now that is rebif which is the sub cutaneous form so not SNG001. Very annoyingly that it doesn't say more...

[peachie 74] 13/4/2020 08:18

Adults with COVID-19 admitted to participant hospitals can join this study. Eligible patients will be asked to sign to show they understand the possible risks and benefits and consent to joining the study. The medical team responsible for each patient will check whether any of the study treatments would definitely be unsuitable.

After those checks, brief identifying details and any other conditions are digitally recorded for the patient, who is then randomly allocated to one of the study options. This may or may not involve one of the study treatments. Neither the patient nor the medical staff choose which of the study options a patient will receive, as a computer makes this allocation at random.

Critical anonymized information for the trial will only be collected at the randomization stage and when the patient is discharged or dies: which study drugs were given (and for how many days); whether ventilation or intensive care was received (and, if so, when it began), date of discharge, or date and cause of death while still in hospital.

Interim trial analyses are monitored by a Global Data and Safety Monitoring Committee, which is an independent group of experts.

Countries, or particular groups of hospitals, may want to collaborate in making further serial measurements or observations, relating to areas such as virology, blood gases or chemistry and lung imaging. It also possible to incorporate documentation of other aspects of disease status, for example, through linking in electronic healthcare records and routine medical databases. While well-organised additional research studies of the natural history of the disease or of the effects of the trial treatments could well be valuable, they are not core requirements.

Adults (age ≥18 years) recently hospitalised, or already in hospital, with confirmed COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study treatments will be randomly allocated between

● Local standard of care,

OR local standard of care plus one of

● Remdesivir

● Chloroquine or Hydroxychloroquine

● Lopinavir with Ritonavir

● Lopinavir with Ritonavir plus Interferon beta-1a.

Underlying conditions recorded are: diabetes, heart disease, chronic lung disease, chronic liver disease and asthma, extending to HIV and tuberculosis in the African region.

Severity of illness at entry is determined by recording: shortness of breath, being given oxygen, already on a ventilator, and, if lungs imaged, major bilateral abnormality.

[peachie 74] 13/4/2020 08:17

hxxps://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

[nobbygnome] 13/4/2020 07:06

But just to say that is the Recovery trial as far as I can see and although SNG001 was in the protocol, it's not in the trial. SG016 is th only trial going on with the drug at the moment which is the correct approach IMHO. One well run trial with a clear endpoint is the way to go. You have to say the company has played a blinder so far; hats off to Richard and the rest of the team!

[nobbygnome] 13/4/2020 07:03

Ok ok. He does dig out good information so I will reinstate him.

[a.fewbob] 13/4/2020 05:36

Well I wasn’t around then but I can say that I think he’s a excellent poster and should be reinstated ASAP.

[torreskid] 13/4/2020 00:50

he received an inhalation of SNG100 and that stimulated/activated his Ramping reflexes, and it was beyond the expectations of the monitoring committee (NG) hehe

[torreskid] 13/4/2020 00:48

red carded for excessive ramping

[a.fewbob] 12/4/2020 23:57

Why the hec isn’t Lith on this thread???????

[a.fewbob] 12/4/2020 23:56

Courtesy of Lith from the other thread!!

Saudi Arabia approves Interferon B test in 7 hospitals

STOP PRESS.....JUST RELEASED A FEW MINS AGO:

13 APR 2020 (yes,its tomorrow in Saudi)


Saudi Arabia’s Food and Drug Authority (SFDA) approved on Sunday conducting an internationally refereed clinical trial for coronavirus (COVID-19) medication in seven hospitals in the Kingdom.

The clinical trial titled “An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care” aims to obtain reliable data related to the effectiveness and safety of a number of antivirals in treating coronavirus: Remdesivir, Chloroquine, Lopinavir with Ritonavir and Interferon Beta 1b.

[the patient investor] 12/4/2020 22:35

NEVER stated that
nor i said it won't

[nobbygnome] 12/4/2020 22:23

There may be an RNS this week but it most definitely will not be the result of the trial.

[a.fewbob] 12/4/2020 22:05

Yep,

This company really is in the right place at the right time!

[the patient investor] 12/4/2020 21:52

RNS IS NEXT WEEK

[141jaffa] 12/4/2020 20:09

I'm sure that I read / heard in the last few days also that respiratory related events were the second highest cause for hospital admissions ( UK).....So even post CV19 this hopefully has legsI also noted from Synairgen Website 2017 trial info ;" Secondly, a novel point of care diagnostic tool has been developed which enables rapid confirmation of the existence of a respiratory viral infection when patients present themselves at the hospital or trial site. This enables us to treat only those patients who are infected with a virus, significantly reducing the number of subjects required to show the potential effect of SNG001. Clearly this has significant benefits in the future, allowing accurate prescribing of an anti-viral therapy quickly to those patients who could benefit from treatment." To me this seems even more significant .... if diagnosis could be done at a GP / Med Centre instead, how many people may not then need hospitalization ?????

[nobbygnome] 12/4/2020 19:57

Completely different from IMM as there is sound evidence that the drug will work. Of course there is no guarantees but it was the complete opposite with Lupuzor as all the data suggested it was unlikely to work. I know that's not what all the rampers said but that was the truth if you understood the science behind the drug and lupus, which is a very tricky indication.

[spawny100] 12/4/2020 19:55

I have a small punt here but the shades of IMM here are giving me a strong sense of deja vu. Many posts here are virtually identical to ones over there a few years back. Once bitten twice shy.

[thwarnts] 12/4/2020 19:48

I'm 61 on the 18th of May and I'll still have to wait for the results.

Thank you very much Nobby for your input in this thread and response to Questions today.
Good luck to all genuine share holders